In other recent news, Madrigal Pharmaceuticals has received European Commission approval for its MASH treatment, Rezdiffra, marking it as the first approved medication for this liver condition in the ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...

Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL) stock gained Wednesday after the European Commission approved its MASH treatment REZDIFFRA, making it the first approved medication for this ...

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Rezdiffra is now the first and only approved therapy in the European Union (EU) for the treatment of MASH. Bill Sibold, Chief Executive Officer of Madrigal, stated, “This approval of Rezdiffra marks a ...

“Prior to Wegovy, there was only one other FDA-approved medication for MASH — Rezdiffra — so treatment options have been quite limited,” Dr. Kardashian says.